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 Synopsis 35 
Objectives: 36 
This study characterized the eleven most predominant serotypes of invasive S. pneumoniae infections 37 
collected by the annual SAVE study in Canada, between 2011 and 2015. 38 
Methods: 39 
A subset of the eleven most predominant serotypes (7F, 19A, 22F, 3, 12F, 11A, 9N, 8, 33F, 15A and 6C) 40 
collected by the SAVE study were analyzed using PFGE and MLST, as well as PCR to identify pilus-41 
encoding genes. WGS analyses were performed on a subset of the above isolates plus a random 42 
selection of background strains. 43 
Results: 44 
Of the predominant serotypes analyzed, 7F, 33F and 19A were obtained more commonly from children 45 
less than 6 years of age, while 15A, 6C, 22F and 11A were more common in adults over 65 years. 46 
Pneumococcal pilus PI-1 was identified in antimicrobial susceptible serotype 15A (61/212) and <10% of 47 
6C isolates (16/188). PI-2 was found in serotype 7F (683/701) and two-thirds of 11A isolates (162/241). 48 
Only serotype 19A-ST320 possessed both pili. Molecular and phylogenetic analyses identified serotypes 49 
19A, 15A, 6C, 9N and 33F as highly diverse, while 7F, 22F and 11A demonstrated clonality. Antimicrobial 50 
resistance determinants were common within diverse serotypes, and usually similar within a clonal 51 
complex. 52 
Conclusions: 53 
Despite successful use of conjugate vaccines, S. pneumoniae remains a highly diverse organism in 54 
Canada. Several predominant serotypes, both antimicrobial susceptible and MDR, have demonstrated 55 
rapid clonal expansion or an increase in diversity. As S. pneumoniae continues to evolve in Canada, WGS 56 
will be a necessary component in the ongoing surveillance of antimicrobial-resistant and expanding 57 
clones. 58 
 Introduction 59 
 Streptococcus pneumoniae is a highly diverse organism capable of causing invasive disease in 60 
children, older adults and immunocompromised individuals.1 The primary virulence factor of this 61 
pathogen is the polysaccharide capsule, which is crucial for immune evasion; extensive study of the 62 
capsule has led to identification of 97 capsular serotypes.2 Historically, only a small number of these 63 
serotypes have accounted for the majority of invasive pneumococcal disease (IPD).1 Those serotypes 64 
most commonly causing invasive disease were targeted by pneumococcal conjugate vaccines (PCV), 65 
which were utilized in Canada beginning in 2002 and have led to widespread success, including 66 
significant overall decreases in IPD, particularly those due to vaccine serotypes.3 However, after using 67 
PCVs (7-valent, 13-valent) for over a decade in Canada, serotype prevalence has shifted due to both 68 
replacement of vaccine types and vaccine escape through capsular switching events.3–6  69 
 During the period of PCV development and use, antimicrobial and MDR in S. pneumoniae has 70 
remained a constant concern, escalated by the worldwide dissemination of resistant and MDR 71 
international clones. The Pneumococcal Molecular Epidemiology Network (PMEN) was established in 72 
1997 to both standardize the classification and create a global collection of resistant clones. Prior to 73 
PCV-7 use, most vaccine serotypes (4, 6B, 9V, 14, 18C, 19F, 23F) had at least one widely disseminated 74 
PMEN clone of concern demonstrating antimicrobial resistance and extensive clonal expansion. Of note 75 
were penicillin-resistant Spain9V-3, macrolide-resistant England14-9, and MDR Spain23F-1, Spain6B-2 and 76 
Taiwan19F-14.7 While use of PCV-7 reduced the impact of these particular clones, others became 77 
increasingly prevalent in the post-PCV-7 era, including Netherlands3-31, Netherlands7F-39 and MDR 78 
serotype 19A-ST320 isolates related to Taiwan19F-14.5,8 More recently in Canada, PCV-13 use has been 79 
associated with a greater prevalence of the highly clonal serotype 22F (ST433), as well as MDR isolates 80 
related to Sweden15A-25.6,9,10 81 
 As noted by Klugman in 2002, genetic analysis of these successful international clones has been 82 
crucial in understanding the spread of antimicrobial resistance in S. pneumoniae.11 Previously, subtyping 83 
methods were used to identify genetic relatedness and genes or mutations associated with resistance. 84 
Many laboratory “gold standards” currently rely on subtyping methods such as PFGE or MLST, despite 85 
the limited amount of information they provide.12 In recent years, WGS has become the method of 86 
choice to characterize isolates due to the rapidly decreasing cost, short time to completion and 87 
unambiguous examination of the total genetic content of a strain at the single nucleotide level.12 88 
 The S. pneumoniae Serotyping and Antimicrobial Susceptibility: Assessment for Vaccine Efficacy 89 
in Canada (SAVE) study is an annual study which began in 2011, after PCV-13 introduction in Canada. 90 
The purpose of the current study was to characterize the eleven most predominant serotypes (7F, 19A, 91 
22F, 3, 12F, 11A, 9N, 8, 33F, 15A, 6C) collected by the SAVE study using PFGE, MLST and pilus PCR, as 92 
well as WGS analyses to determine population structure, phylogenomic relationships and antimicrobial 93 
resistance determinants for a subset of these isolates.  94 
Materials and Methods 95 
Bacterial isolates 96 
From January 2011 to December 2015, S. pneumoniae isolated from sterile body sites by 97 
participating Canadian provincial public health and hospital laboratories were forwarded to the Public 98 
Health Agency of Canada-National Microbiology Laboratory (PHAC-NML) in Winnipeg, Canada.  As part 99 
of an ongoing collaboration between the Canadian Antimicrobial Resistance Alliance (CARA) and PHAC-100 
NML, PHAC-NML forwarded their collection of invasive isolates of S. pneumoniae isolates from eight 101 
Canadian provincial laboratories (Saskatchewan, Manitoba, Ontario, Quebec, Nova Scotia, Prince 102 
Edward Island, Newfoundland and Labrador, and a portion of isolates collected from New Brunswick) to 103 
CARA for antimicrobial susceptibility testing.  For the SAVE study, regional analysis were conducted as 104 
 Western (Saskatchewan and Manitoba), Central (Ontario and Quebec) and Eastern (New Brunswick, 105 
Nova Scotia, Prince Edward Island, and Newfoundland and Labrador). 106 
In total, 6207 invasive isolates of S. pneumoniae collected as part of SAVE study between 2011 107 
and 2015 were forwarded to the CARA for antimicrobial susceptibility testing. Patient gender and age 108 
information was available for 5980 (96.3%) and 6072 (97.8%) of the isolates, respectively. The annual 109 
numbers of isolates were: 1379 isolates from 2011, 1285 from 2012, 1138 from 2013, 1210 from 2014, 110 
and 1195 from 2015. 111 
Antimicrobial susceptibility testing 112 
Antimicrobial susceptibility testing was performed at the Winnipeg Health Sciences Centre 113 
(Winnipeg, Manitoba, Canada) using the CLSI standard broth microdilution method13,14 with custom-114 
designed, in-house prepared, 96-well microtitre panels containing doubling-dilutions of antimicrobial 115 
agents in cation-adjusted Mueller-Hinton broth supplemented with 4% lysed horse blood.  All isolates 116 
were tested against penicillin, ceftriaxone, cefuroxime, clarithromycin, clindamycin, telithromycin, 117 
levofloxacin, moxifloxacin, linezolid, trimethoprim/sulfamethoxazole, doxycycline, tigecycline, 118 
chloramphenicol and vancomycin.  MICs were interpreted as susceptible, intermediate or resistant using 119 
CLSI MIC breakpoints.13  MDR was defined as resistance to three or more classes of antimicrobial agents 120 
(penicillin resistance was defined using the CLSI breakpoint for oral penicillin V, MIC ≥2 mg/L). Isolates 121 
resistant to five or more classes of antimicrobials were considered extensively drug resistant (XDR). 122 
Serotyping 123 
Serotyping was performed using the Quellung reaction15 using pool, group, type and factor 124 
commercial antisera (Statens Serum Institute, Copenhagen, Denmark). Isolates for which a serotype was 125 
not determined by a Quellung reaction were confirmed as S. pneumoniae by rpoB gene sequencing.16 126 
 127 
PFGE, MLST and Pilus PCR 128 
 Ten randomly selected isolates of each of the eleven most common serotypes per year (7F, 19A, 129 
22F, 3, 12F, 11A, 9N, 8, 33F, 15A, 6C; 50 of each serotype, 550 total isolates) were characterized for 130 
genetic relatedness by PFGE and MLST. PFGE was performed as previously described.17,18 Gels were 131 
analysed using BioNumerics® Software (Applied Maths Inc, Austin, TX). Isolates with ≥ 80% relatedness 132 
were considered a cluster. 133 
MLST was performed on the same 550 isolates using methods and primers previously described 134 
at http://pubmlst.org/spneumoniae. Sequences were analysed using Lasergene® SeqMan Pro (DNAStar, 135 
Madison, WI). MLST sequence types (STs) were compared to the Pneumococcal Molecular Epidemiology 136 
Network (PMEN) database (http://www.sph.emory.edu/PMEN) to identify commonly circulating clones. 137 
Minimum spanning trees were generated using PHYLOViZ 2.0 open-source software.19 138 
To assess putative virulence, PCR to determine the presence of pneumococcal pili was 139 
performed using previously described primers.20  140 
Isolate Selection for WGS 141 
A total of 192 isolates were selected for WGS by the Illumina MiSeq platform. An initial 84 142 
isolates from the SAVE study were specifically selected from the above serotypes due to preliminary 143 
characterization that indicated MDR, novel MLST STs and/or the potential to be a capsular switch 144 
variant. To achieve broader coverage of the diverse pneumococcal population, 78 additional isolates 145 
from SAVE were selected as “background”. These isolates were selected using a random number 146 
generator and included three of each serotype included in the 23-valent pneumococcal polysaccharide 147 
vaccine and up to three of other non-vaccine serotypes to total 78 isolates. To include isolates collected 148 
prior to PCV-13 introduction, 30 invasive S. pneumoniae isolates randomly selected from 2007-2009 149 
were included. These isolates were collected as part of the BESST study;21 only isolates collected from 150 
the same provinces and source as the other 162 isolates were included. To control one of the many 151 
variables, all isolates were selected from the  65-year age category, as this age group had the largest 152 
 and most diverse collection of isolates from which to sample.  Overall, 44 different serotypes were 153 
represented in this analysis. 154 
WGS Data Analysis 155 
Phylogenomic analysis was performed using SNVPhyl, a PHAC-NML custom-built bioinformatics 156 
pipeline22 and reference genome S. pneumoniae R6 (NCBI: NC_003098). Briefly, repeat regions of the 157 
reference genome were identified using MUMMer v.3.2323 and collected into a file of locations to be 158 
excluded from further analysis. MUMMer was run using a minimum length of 150 and a minimum 159 
percent identity of 90. Reads were then mapped to the reference genome using SMALT v.0.7.4 160 
(http://www.sanger.ac.uk/science/tools/smalt), with a k-mer size of 13 and a step size of 6. Variant 161 
calling was performed using both FreeBayes v.0.9.2024 and SAMtools.25,26 FreeBayes detected variants 162 
using a minimum coverage of 10, a minimum mean mapping quality of 30 and an alternate allele 163 
proportion of 0.75. SAMtools was used to confirm the variant calls made by FreeBayes. These SNVs were 164 
filtered and merged, as previously described, to construct a multiple sequence alignment.22 Four isolates 165 
mapped poorly to the reference strain, and were removed from further analysis. PhyML v.3.027 was used 166 
to generate a maximum likelihood phylogenetic tree from this alignment, which was then visualized 167 
using FigTree software (v.1.4.3, http://tree.bio.ed.ac.uk/software/figtree). Phylogenetic clades were 168 
determined using ClusterPicker v.1.2.3 software using the default parameters.28 169 
The presence of acquired resistance genes was determined for SAVE isolates using the 170 
ResFinder 2.1 program.29 This open-source software is freely available from the Center for Genomic 171 
Epidemiology (https://cge.cbs.dtu.dk/services/ResFinder/), and identified resistance genes for 172 
macrolides (mefA, ermB, msrD), tetracyclines (tetM) and chloramphenicol (cat). Genes with 173 
chromosomal mutations conferring resistance were extracted using NCBI BLAST tools30,31 and compared 174 
to those of S. pneumoniae R6. Extracted genes were aligned to the reference sequence using the 175 
ClustalW2 multiple sequence alignment program 32. For the penicillin-binding proteins, DNA sequences 176 
 were translated into amino acid sequences and examined for mutations in the active site motifs of 177 
pbp1A (STMK, SRNVP, KTG), pbp2B (SVVK, SSNT, KTGTA) and pbp2X (STMK, AHSSNV, LKSGT) as 178 
previously described 33,34. Nucleotide sequences of parC, gyrA, and folA/P were examined for previously 179 
described mutations that convey fluoroquinolone and trimethoprim/sulfamethoxazole resistance, 180 
respectively 35,36. 181 
Statistical Analysis 182 
Differences in serotype distribution between the various demographic parameters were 183 
assessed for statistical significance (P <0.05) using a two-tailed Fisher’s exact test (α=0.05). 184 
Results 185 
Isolate Demographics 186 
 Among the S. pneumoniae isolates collected for the SAVE 2011-15 study, the eleven most 187 
predominant serotypes accounted for 65.9% (4092/6207) of isolates (Table 1). The serotype distribution 188 
of these eleven serotypes was evaluated by region and age group. When compared to the 868 isolates 189 
(21.2%) collected from Western Canada, the proportion of serotypes 12F (n=219, 75.3%; P<0.0001) and 190 
8 (n=140, 28.2%; P=0.0124) collected were significantly higher in the West than the other predominant 191 
serotypes. Similarly, when compared to the 2,701 isolates (66%) collected from Central Canada, the 192 
proportion of serotypes 15A (172, 78.2%; P<0.0001), 11A (205, 76.2%; P=0.0005), 7F (n=514, 73.0%; 193 
P=0.0002) and 22F (n=425, 71.1%; P=0.01) were significantly higher than the other predominant 194 
serotypes. Only serotype 19A demonstrated a significantly higher proportion overall in Eastern Canada 195 
(17.6% versus 12.8%, P=0.0017). Of note in the age group distribution are those ages where 196 
pneumococcal disease is most common, particularly young children and older adults. Significant 197 
serotypes in children were 7F, which was more frequently isolated from infants less than one year of age 198 
(n=30, 4.3%; P=0.03), 33F, which was more commonly isolated from those one year to less than two 199 
years of age (n=20, 8.9%; P<0.0001), and 19A, which was more likely isolated from children aged two 200 
 years to less than six years (n=53, 8.8%; P<0.0001). In adults over the age of 65 (n=1,499, 36.6%), there 201 
were four predominant serotypes that were significantly more prevalent than the other serotypes of 202 
interest. These were serotypes 15A (n=126, 57.3%; P<0.0001), 6C (n=116, 56.6%; P<0.0001), 22F (n=270, 203 
45.2%; P<0.0001) and 11A (n=117, 43.5%; P=0.0266). In the adult population (18-<50), serotype 12F 204 
(n=129, 44.3%; P<0.0001) and 8 (n=77, 32.0%; P=0.0002) were most frequently obtained. Except for 205 
serotypes 15A and 33F, isolates were more commonly obtained from males. 206 
Genetic Characterization 207 
Pneumococcal Pili 208 
Overall, 3878 isolates with a predominant serotype had full PCR results for both PI-1 and PI-2 209 
(Table 2). Several serotypes had little to no association with either pilus, including 22F, 3, 12F, 9N, 8 and 210 
33F. Isolates with PI-1 genes (serotypes 6C, 15A and 19A) were not commonly associated with a MDR 211 
phenotype. Of the 16 serotype 6C isolates (8.5%) that harboured PI-1, only one was MDR; however, 212 
two-thirds of the same 16 isolates were resistant to trimethoprim/sulfamethoxazole. Despite being a 213 
commonly MDR serotype, 15A isolates containing PI-1 (n=61, 28.8%) expressed little resistance and 214 
were not associated with a MDR phenotype. Serotype 19A demonstrated just over 5% MDR in isolates 215 
containing PI-1 (n=257, 44.5%). PI-2 was the more common pilus type overall, likely due to 97.4% 216 
(683/701) of serotype 7F isolates (the most common serotype over the study period) possessing PI-2. 217 
This was the only instance where almost the entire serotype cohort demonstrated one specific genotype 218 
(apart from having no pilus genes). Over half of serotype 11A isolates (n=162, 67.2%) possessed PI-2. 219 
Neither serotype 7F or 11A demonstrated an appreciable amount of MDR when PI-2 genes were 220 
present. The clearest association of pneumococcal pili with MDR was found with the dual PI-1/PI-2 221 
genotype demonstrated by serotype 19A. Of the serotype 19A isolates tested, 21.1% demonstrated the 222 
dual genotype and 95.9% of these isolates were MDR or XDR. 223 
PFGE, MLST and WGS 224 
  Isolates clustered similarly using both PFGE (data not shown) and MLST (Figure 1). Although the 225 
number of isolates typed by WGS was much lower, phylogenomic analysis provided a more in-depth 226 
perspective on many of the predominant serotypes and their relatedness to other types (Figure 2). 227 
Illumina MiSeq sequencing resulted in an average of 539 336 reads/genome with an average genome 228 
coverage of 77x. De novo assembly yielded an average contig and N50 length of 59 983 bp and 121 439 229 
bp, respectively. 230 
 Serotype 19A, a commonly MDR serotype, was found to be highly variable in this study. Thirteen 231 
STs were identified by MLST, indicating high diversity in this group of isolates. The most common types 232 
were ST320, a frequently MDR type related to international clone PMEN14, and ST695, associated with 233 
susceptibility to all antimicrobials except for clarithromycin. Additionally, a smaller cluster of serotype 234 
19A isolates typed as identical or related to PMEN37, an international clone originally identified in 235 
serotype 15B. Of these many STs, the only types to demonstrate the dual PI-1/PI-2 genotype mentioned 236 
above were those related to PMEN14. Aside from one large cluster of isolates related to PMEN14, 237 
serotype 19A isolates were difficult to pinpoint in the phylogenetic analysis because of their relatedness 238 
to several different serotypes, resulting in their distribution throughout many smaller clusters of 239 
background isolates. Fourteen of 32 serotype 19A isolates that were sequenced were not ultimately 240 
related to PMEN14. However, these isolates were instead related to PMEN clones 1, 3, 9, 21, 25, 30, 32 241 
and 37, and thus related in various degrees to isolates of serotypes 3, 4, 9V, 14, 15A, 15B, 17F, 19F, 21, 242 
23F and 24F. This indicates that serotype 19A isolates likely frequently participate in recombination. 243 
 Like serotype 19A, serotype 15A (also frequently MDR) demonstrated numerous STs in this 244 
study. Fourteen STs identified by MLST were found to be associated with serotype 15A; however, half of 245 
these were identical or related to ST63, a frequently MDR type designated PMEN25. Isolates related to 246 
this clone had a common resistance pattern of clarithromycin, clindamycin and doxycycline, with 247 
occasional resistance to penicillin or trimethoprim/sulfamethoxazole. The other seven STs were 248 
 predominantly susceptible to all antimicrobials and over half of these isolates possessed PI-1 genes. 249 
Most serotype 15A isolates clustered together in the phylogenetic analysis, however a few were more 250 
highly related to PMEN3 and PMEN30 (serotypes 9V and 21, respectively). 251 
 Two other predominant serotypes that demonstrated high diversity were 6C and 9N. Serotype 252 
6C demonstrated 20 different STs by MLST, the most of any serotype in this study. As opposed to a large 253 
cluster of closely related types, serotype 6C had a few smaller clusters containing two or three STs, with 254 
many others differing by three or more alleles (Figure 1). Despite the large number of STs, only two 255 
were related to an international clone: ST338, an international clone (PMEN26) originally associated 256 
with serotype 23F, and ST5241, a double-locus variant (DLV) of PMEN26. Much of the MDR in the typed 257 
serotype 6C isolates was attributed to this cluster, specifically ST5241, which demonstrated resistance to 258 
clarithromycin, clindamycin and doxycycline. Despite being relatively dispersed in the MLST minimum 259 
spanning tree, the whole genomes of serotype 6C isolates clustered together, except for the PMEN26-260 
related strain that was more closely related to serogroup 23 background strains. Only one isolate with 261 
typing data was positive for PI-1 genes, making it difficult to determine if a pattern exists between PI-1 262 
presence and ST for serotype 6C. Serotype 9N demonstrated 12 STs by MLST, most of which were 263 
contained in a large cluster centred on ST66, a single-locus variant (SLV) of PMEN18; phylogeny 264 
presented similar results (Figure 1 and 2). Despite this clone being known for its resistance to 265 
antimicrobials, most isolates with this type were fully susceptible to all agents. A small number of 266 
isolates were variants of PMEN34, commonly associated with serotype 12F. Only one isolate was MDR, 267 
with resistance to clarithromycin, clindamycin, doxycycline and penicillin, but it was not related to either 268 
international clone. 269 
 Serotype 7F, the most commonly isolated serotype in the SAVE study, was also the most clonal 270 
of the serotypes studied. All but one isolate typed as ST191 by MLST, identical to the PMEN39 271 
international clone originally isolated in the Netherlands. Interestingly, the ST191 isolates typed by WGS 272 
 were the most distantly related to the rest of the population, clustering distantly from all other isolates 273 
(Figure 2). One serotype 7F isolate demonstrating resistance to clarithromycin, clindamycin and 274 
doxycycline typed as ST63 and clustered accordingly with the MDR 15A isolates in the maximum 275 
likelihood tree. Serotype 22F demonstrated similar results to serotype 7F. Over 95% of serotype 22F 276 
isolates typed by MLST fell into a cluster founded by ST433. Additionally, in both MLST and WGS there 277 
were serotype 22F isolates that clustered with ST63; these isolates typed as ST9352, a SLV of ST63 that 278 
demonstrated the common ST63 resistance pattern, with the addition of levofloxacin resistance. 279 
 Two serotypes that clustered closely together by both MLST and WGS were 11A and 33F. 280 
Serotype 11A was relatively clonal, with most isolates typing as ST62 and just over half exhibiting PI-2 281 
genes. One isolate typed as ST156, identical to commonly PI-1 piliated and antimicrobial resistant 282 
international clone PMEN3; the serotype 11A isolate in question also possessed PI-1 genes and 283 
demonstrated resistance to penicillin and trimethoprim/sulfamethoxazole. Unlike serotype 11A, 284 
serotype 33F demonstrated more diversity in MLST types. Eight STs were identified for serotype 33F, 285 
four of which were newly assigned during the study period. Visually, these isolates appeared separated 286 
in the minimum spanning tree (Figure 1); however, despite the variability in ST, all serotype 33F isolates 287 
clustered closely in the phylogenetic analysis. Interestingly, despite appearing highly related to serotype 288 
11A in the minimum spanning tree, phylogenetic analysis including background serotypes revealed that 289 
serotype 33F demonstrated greater relatedness to serotype 18C, a type not studied in detail. The cluster 290 
highlighted as serotype 33F in Figure 2 was determined by the ClusterPicker program and is comprised 291 
of not only serotype 33F isolates, but also several 18C isolates.  292 
 Serotype 3 was an interesting case; by MLST, serotype 3 appeared very clonal. Almost 90% of 293 
the isolates tested were ST180 (PMEN31) or a SLV. However, when examining the phylogeny of these 294 
isolates, ST180 was comprised of two distinct clades (Figure 2). Clade I was completely susceptible to all 295 
antimicrobials, while Clade II demonstrated resistance to chloramphenicol, clarithromycin, doxycycline 296 
 and often clindamycin. Additionally, one isolated typed as ST177 by both MLST and WGS clustered with 297 
other isolates related to PMEN21 (originally represented by serotype 19F). 298 
 Serotypes 8 and 12F were similar in the fact that they demonstrated two distinct clusters of 299 
isolates by MLST – one related to an international clone and the other not. The largest serotype 12F 300 
cluster was founded on ST218, an international clone from Denmark (PMEN34), and isolates were often 301 
resistant to clarithromycin. In sharp contrast, the other cluster shared no MLST alleles in common with 302 
other isolates of the same serotype and was MDR, with resistance to clarithromycin, clindamycin and 303 
doxycycline. Phylogenetic analysis determined that ST218 isolates were more related to other 304 
international clones, particularly PMEN4, while the MDR isolates clustered near several background 305 
serotypes, including 31, 10A and 35F. Unlike serotype 12F, the largest cluster of serotype 8 isolates was 306 
not related to an international clone (PMEN33, ST53). Less than 20% of isolates typed by MLST were 307 
part of this cluster and no isolates with a sequenced whole genome demonstrated a type related to this 308 
clone. Most serotype 8 isolates clustered around founder ST1480, a type that is six alleles different from 309 
ST53. Isolates clustered similarly in the maximum likelihood tree, with 38 and 22F representing the most 310 
closely related serotypes. Only one serotype 8 isolate tested had an MDR phenotype; this ST63 isolated 311 
clustered accordingly in the phylogenetic analysis and had the characteristic ST63 resistance pattern as 312 
described above. 313 
Antimicrobial Resistance Determinants 314 
Of the 162 isolates from SAVE with whole genomes available, 27 (16.7%) demonstrated 315 
discrepancies between genotype and phenotype for one or more antimicrobials. After repeating the 316 
susceptibility testing in triplicate, two isolates would not grow for repeat testing and were therefore 317 
removed from the analysis of resistance genes, leaving 160 SAVE genomes available for this analysis. 318 
After retesting, four discrepancies remained. The genes and mutations identified are outlined in Table 3. 319 
Acquired Resistance Genes 320 
 Both mefA and ermB macrolide resistance genes were common amongst tested isolates. 321 
Overall, ermB (n=48, 30.0%) was more commonly identified than mefA (n=17, 10.6%) and was found in a 322 
larger number of serotypes. Both genes conferred high rates of nonsusceptibility to clarithromycin (94.1 323 
and 97.9% for mefA and ermB, respectively); ermB also provided 81.2% of isolates with nonsusceptibility 324 
to clindamycin. Of the two determinants on their own, ermB was more commonly associated with MDR 325 
isolates. The dual mefA+ermB genotype was only present in serotype 19A isolates, specifically ST320 326 
isolates demonstrating an XDR phenotype. However, this dual genotype did not necessarily confer full 327 
resistance to macrolides and lincosamides, with isolates demonstrating 94.4% and 61.1% 328 
nonsusceptibility, respectively. Upon further inspection, six of 18 isolates that contained the dual 329 
mefA+ermB genotype but were clarithromycin susceptible, intermediate, or demonstrated only low-330 
level resistance (1 mg/L) contained a truncated version of the ermB gene caused by a premature stop 331 
codon at base 642. 332 
The tetM gene associated with tetracycline resistance was present in 40.0% (n=64) of isolates 333 
and conferred 93.7% nonsusceptibility to doxycycline. Four isolates carried an intact tetM gene but were 334 
not resistant to doxycycline, perhaps indicating a nonfunctional gene. Presence of tetM was associated 335 
with 19 different serotypes and a large proportion of these isolates were MDR (89.1%). Only a small 336 
number of isolates, predominantly serotype 3, Clade II, carried the cat gene (n=8, 5.0%). However, 337 
possession of this gene was consistently associated with resistance to chloramphenicol (100% 338 
resistance) and all isolates carrying cat were also MDR.  339 
Chromosomal Mutations 340 
Alterations in key motifs of PBPs were discovered in 75/160 (46.9%) isolates with whole 341 
genomes available (Table 3), particularly in serotypes 19A and 15A. The most common single alteration 342 
was a lone Thr451Ala mutation in the SSNT motif of pbp2B; this mutation was found in a variety of 343 
serotypes and was associated with increased penicillin-nonsusceptibility. Conversely, isolates with solely 344 
 a pbp2X alteration were fully susceptible to penicillin. No isolate was found to contain mutations in 345 
pbp1A alone. The highest penicillin MICs were most commonly associated with mutations in all three 346 
PBPs (100% nonsusceptibility overall, Table 3). The most common set of alterations was Thr371Ser in 347 
STMK and Pro432Thr in SRNVP of pbp1A, Thr451Ala in SSNT and Ala624Gly in KTGTA of pbp2B and 348 
Thr338Ala in STMK and Leu546Val in LKSGT of pbp2X. This pattern of alterations was exclusively 349 
associated with ST320-19A isolates with MDR/XDR phenotypes.  350 
Mutations in the quinolone-resistance determining regions (QRDR) of parC and gyrA were 351 
uncommon, with only 14/160 isolates (8.8%) demonstrating alterations (Table 3). Three isolates 352 
exhibited alterations in the QRDR of parC, two with Ser79Phe and one with Ser79Tyr. These mutations 353 
conferred 66.7% nonsusceptibility to levofloxacin, the fluoroquinolone that preferentially targets parC. 354 
Similarly, three isolates were identified with Ser81Phe mutations in gyrA. These isolates demonstrated 355 
33.3% susceptibility to moxifloxacin, which preferentially targets gyrA. Eight isolates were determined to 356 
have mutations in the QRDR regions of both parC and gyrA. Four isolates contained Ser79Phe and 357 
Ser81Phe mutations in parC and gyrA, respectively, two contained Ser79Tyr and Ser81Phe and two 358 
contained Ser79Phe and Ser81Leu. This last set of isolates were the ST9352-22Fs previously discussed as 359 
being related to ST63. Overall, half of the isolates demonstrating a QRDR mutation were also MDR or 360 
XDR (Table 3). Other than serotype 22F as mentioned above, mutation patterns in parC and gyrA were 361 
not specific to serotype. However, mutations in one or both genes were essential for fluoroquinolone 362 
resistance as isolates with neither mutation were fully susceptible to both levofloxacin and moxifloxacin. 363 
Mutations in folA and localized insertions in folP were identified in 47/160 isolates (29.4%) 364 
(Table 3). Although none of these isolates exhibited the Ile100Leu mutation in folA alone, ten isolates 365 
contained solely a folP insertion and provided either intermediate resistance or susceptibility to 366 
trimethoprim/sulfamethoxazole. Dual alterations of both folA and folP were more commonly identified 367 
than a single mutation (37/47). The combination of both mutations conferred 100% nonsusceptibility to 368 
 trimethoprim/sulfamethoxazole and were more commonly associated with MDR (83.8%). Interestingly, 369 
there were seven different folP insertions of one or two amino acids between codons 59 and 69 that 370 
were associated with varying levels of resistance, MDR and serotype specificity. The most common 371 
insertion consisted of an extra Glu-Ile (EI) after codon 66 of folP. This alteration was present in 372 
combination with folA-Ile100Leu in 17 ST320-19A isolates, was associated with the highest 373 
trimethoprim/sulfamethoxazole MICs, and isolates were either MDR or XDR. These serotype 19A 374 
isolates were the same as those mentioned above which demonstrated the most common set of 375 
alterations in all three PBPs. 376 
Discussion 377 
 The use of conjugate vaccines to combat IPD has resulted in dramatic shifts in serotype 378 
distribution throughout Canada.4 This study characterized the most predominant serotypes circulating in 379 
Canada in the years following PCV-13 introduction. The findings of this study indicate that S. 380 
pneumoniae remains a highly diverse organism, with several serotypes, both susceptible and MDR, 381 
demonstrating either clonal expansion or an increase in diversity. 382 
 This study identified associations between several predominant serotypes and vaccine-eligible 383 
age groups: serotypes 7F, 19A and 33F in children less than six, and 15A, 6C, 22F and 11A in adults over 384 
the age of 65. A recent review of worldwide serotype distribution data corroborated many of these 385 
findings, with slight variations based on geographic location and specimen source.37 In particular, 386 
serotypes 6C and 33F were more commonly noted here than in the systematic review. While serotype 387 
33F has been noted for its high invasive capacity in children, 6C has been more commonly isolated as a 388 
nasopharyngeal carrier with a lower capacity for invasion.38 The high prevalence of serotype 6C IPD 389 
isolated from adults over 65, particularly in Central Canada, may indicate the occurrence of an outbreak, 390 
and that older adults are more vulnerable to IPD caused by this serotype than children. 391 
 Interestingly, serotypes 12F and 8 were common in adults aged 18-<50. Serotype 12F was most 392 
common in Western Canada, where 75.3% of 12F isolates were collected. A study performed in Alaska 393 
noted that this serotype is not normally associated with nasopharyngeal carriage in healthy people, but 394 
is instead a common cause of IPD outbreaks;39 reports have described outbreaks of serotype 12F IPD in 395 
the United States and most recently, Winnipeg, Manitoba, Canada in 2008-11.39–41 As serotype 12F 396 
collection has remained high in Western Canada since this time, it is possible that the outbreak has 397 
continued. Interestingly, two serotype 12F isolates analysed in the current study were MDR, as opposed 398 
to solely possessing macrolide resistance like many ST218 isolates.41 As serotype 12F is prone to causing 399 
outbreaks, these new MDR clones are of particular interest for future study. Serotype 8 was also 400 
common in adults aged 18-<50, and has been similarly noted in Spain to be generally susceptible to 401 
antimicrobials and largely isolated from adult patients. Interestingly, Spain has experienced clonal 402 
expansion of MDR serotype 8 strains related to PMEN25 (ST63).42 These isolates were resistant to 403 
macrolides, lincosamides, tetracyclines, and fluoroquinolones; initially restricted to HIV-positive patients 404 
in Madrid, this clone spread through adults in nine other regions.42 One such isolate was collected and 405 
analyzed in the current study; however, this isolate did not demonstrate fluoroquinolone resistance. 406 
MDR serotype 8-ST63 should be monitored closely in Canada as it could become a strain of concern in 407 
normally healthy adult patients. 408 
 In general, serotypes that demonstrated high levels of diversity in this study were also those 409 
that had the highest rates of MDR and demonstrated strong associations with a specific resistance 410 
pattern.43 Serotypes 6C, 15A, 19A and 33F were commonly resistant to antimicrobials, with resistance 411 
mediated by the acquisition of foreign resistance determinants, specifically ermB and tetM. A recent 412 
study by Croucher et al. identified a correlation between serotype diversity and the total number of 413 
recombination events experienced;44 the diversity of the above serotypes would indicate high 414 
recombination frequencies and thus increased chances of obtaining acquired resistance determinants. 415 
  Of the diverse serotypes noted above, 19A appeared to participate most frequently in 416 
recombination involving the capsule. In this study alone, serotype 19A was the donor strain for multiple 417 
putative recombinations involving serotypes 14, 15A, 15B, 19F, 21 and 23F. Several whole genome 418 
studies of S. pneumoniae in other countries have noted similar recombinations, including Bulgaria, 419 
Germany, Russia and the United States.45–48 Importantly, penicillin resistance, a particularly common 420 
trait of serotype 19A, is mediated by point mutations in PBP genes located on either side of the capsular 421 
polysaccharide operon of S. pneumoniae. A study of isolates from an East Asian population noted that 422 
recombination has facilitated the consistent spread of -lactam resistance amongst the pneumococcal 423 
population. Similarly, folA genes demonstrated manifestations of recombination; interestingly, there 424 
was no association between folP insertions and recombination.49 425 
Despite the variability within serotype 19A strains, most studies have focussed on the ST320 426 
clone. A Canadian study followed the development of serotype 19A from 1993-2008 and concluded that 427 
the emergence of ST320 was the combinatory result of vaccine selection pressure, antimicrobial 428 
pressure and the propensity of S. pneumoniae to undergo recombination.5 This strain was originally 429 
identified as a vaccine escape recombinant in the post-PCV-7 era and has continued to be a successful 430 
clone well into the use of PCV-13, despite serotype 19A being included in the formulation.45 431 
Approximately 25% of serotype 19A isolates typed by MLST in the current study were ST320. Despite 432 
possessing the dual mefA/ermB genotype, tetM, alterations in all three PBPs, folA mutations, folP 433 
insertions and both pneumococcal pili, ST320 isolates collected in this study were rarely fluoroquinolone 434 
resistant. The high fitness cost associated with mutations in DNA replication enzymes ensures that, at 435 
least for the time being, ST320 isolates are susceptible to at least one antimicrobial class. 436 
 One of the most clonal serotypes described in this study was 7F; almost all isolates tested were 437 
ST191 or a variant related to PMEN39 and few were resistant to antimicrobials. Once the most common 438 
serotype isolated by the SAVE study, use of PCV-13 resulted in a dramatic decrease in prevalence of 439 
 serotype 7F.43,50 Studies have estimated the specific PCV-13 vaccine effectiveness for serotype 7F to be 440 
over 90%;51 the clonal nature of this serotype, and thus the lack of serotype variability may have 441 
contributed to the success of opsonophagocytic killing of serotype 7F in PCV-13. A similar serotype of 442 
interest in this study was 22F, ranking as the most commonly collected serotype in SAVE 2015.43 The 443 
predominant serotype 22F clone was ST433, a finding that has been noted in many other countries, 444 
including Japan, Sweden and the United States.52–54 Many serotype 22F isolates were resistant to 445 
clarithromycin;43 in this study, resistance was found to be mediated by either mefA or ermB, though a 446 
similar Canadian study noted mefA to be the most common macrolide resistance determinant in 447 
serotype 22F.10 As serotype 22F shares many properties with vaccine-success serotype 7F, it is possible 448 
that 22F will react similarly to vaccine use when PCV-15 (PCV-13 plus 22F and 33F) becomes available. 449 
 A type that demonstrated little diversity by MLST was serotype 3, with most isolates belonging 450 
to the predominant ST180 clonal complex (PMEN31). However, phylogenetic analysis of serotype 3 451 
revealed two different clades of isolates with specific antimicrobial resistance patterns. A recent 452 
phylogenetic analysis of a small international collection of CC180 isolates indicated that most were 453 
unaffected by recombination, having little diversity and appearing “frozen” from an evolutionary 454 
standpoint (clade I). However, other CC180 isolates in this collection exhibited significant accumulation 455 
of genetic variation, although little antimicrobial resistance was seen (clade II).55 In the current study, 456 
ST180 isolates belonging to clade II often possessed three acquired resistance determinants conferring 457 
resistance to four different antimicrobials; notably, the clade II group was the only cluster of isolates in 458 
this study to consistently possess cat. As the previously discussed study collected isolates from 1993-459 
2007, it is possible that the later collection date of the clade II isolates in this study (2011-14) allowed 460 
increased time to acquire resistance genes through recombination events. A more recent study by 461 
Azarian et al. included isolates collected from 24 different countries from 1993-2014. It was determined 462 
that 19% of CC180 isolates belonged to clade II and that approximately 26% of clade II isolates 463 
 possessed ermB and tetM, in comparison to one-half of ST180 isolates belonging to clade II and 100% 464 
possessing ermB/tetM in the current study.56 Interestingly, this study also determined that clade I and 465 
clade II ST180 isolates differed in their surface protein antigens, most notably pspA. Clade I isolates 466 
possessed family 2 pspA variants, while clade II isolates possessed family 1 variants.56 The prevalence of 467 
clade II isolates, frequent antimicrobial resistance and different antigen profiles indicates the need for 468 
additional screening of serotype 3 isolates in Canada. However, as MLST does not discriminate between 469 
isolates of the same ST, WGS will be crucial in separating these very different clades of ST180. 470 
The presence of pneumococcal pili has been previously described as a clonal property.20,57 In this 471 
study, there was a clear correlation between pilus presence and several predominant clones. This 472 
included serotype 7F-ST191 (PI-2), 19A-ST416 and ST695 (PI-1) and 19A-ST320 (PI-1 and PI-2), all of 473 
which have been previously noted in studies performed in Italy, Portugal and the United States.20,35,57,58 474 
Though other studies have also observed the lack of pili in MDR serotype 15A-ST63 isolates,35 this is one 475 
of few studies to note that susceptible 15A-ST58 isolates often possess PI-1. Interestingly, this study had 476 
comparatively more PI-2 piliated serotype 11A isolates than a recent Active Bacterial Core surveillance 477 
study in the United States.35 The American study found that only 38% of serotype 11A-ST62 isolates 478 
contained PI-2 in comparison to over 60% in the current study. In general, piliation in ST62 isolates has 479 
been variable depending on the study; Zahner et al. noted that this variability in PI-2 presence indicates 480 
that piliation is not essential for serotype 11A to cause invasive disease.20 A recent study illustrated an 481 
overall decline in pneumococcal pilus frequency, as many piliated types were contained in PCV-7.59 It is 482 
reasonable to assume that the frequency of pili will decrease even more with PCV-13 use, as the 483 
prevalence of disease caused by commonly isolated and piliated serotypes 7F and 19A should decrease 484 
after a number of years. 485 
This study is limited by the lack of participation of all Canadian provinces. As Alberta and British 486 
Columbia do not submit isolates, the regional analyses may be skewed due to underrepresentation of 487 
 the Western region. Additionally, submission of IPD isolates to the PHAC-NML is voluntary and passive, 488 
which restricts the reporting of incidence data. Lastly, the small sample size included in the WGS analysis 489 
is only a very small portion of S. pneumoniae isolates collected by the SAVE study. Inclusion of more 490 
isolates of interest and more background strains would allow for better representation of the breadth of 491 
genetic diversity in the Canadian pneumococcal population. 492 
The observations made in this study indicate that S. pneumoniae is a pathogen of high genetic 493 
variability, and therefore worthy of further genetic surveillance. S. pneumoniae has demonstrated the 494 
capacity to propagate highly successful clones, such as ST320, ST433 and ST191, while also participating 495 
in frequent recombination to increase genetic diversity and spread antimicrobial resistance genes. 496 
Importantly, this study illustrated the increased ability of WGS to discriminate between closely related 497 
isolates, in comparison to PFGE and MLST. As S. pneumoniae continues to evolve in Canada, WGS will be 498 
crucial to differentiate virulent clones and outbreak strains and in the ongoing surveillance of 499 
antimicrobial resistance. 500 
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 Table 1: Demographic information for the eleven most predominant serotypes collected by the SAVE 2011-2015 study. 672 
Serotype 
(n) 
n (%) of Isolates Associated with Demographic 
Region Age Group (years) Gender 
West Central East <1 1 - <2 2 - <6 6 - <18 18 - <50 50 - <65 65 NGa Male Female NGa 
7F 
(704) 
89 
(12.6) 
514 
(73.0) 
101 
(14.3) 
30 
(4.3) 
4 
(0.6) 
22 
(3.1) 
44 
(6.3) 
216 
(30.7) 
185 
(26.3) 
184 
(26.1) 
19 
(2.7) 
368 
(52.3) 
314 
(44.6) 
22 
(3.1) 
19A 
(603) 
100 
(16.6) 
397 
(65.8) 
106 
(17.6) 
11 
(1.8) 
27 
(4.5) 
53 
(8.8) 
21 
(3.5) 
107 
(17.7) 
164 
(27.2) 
198 
(32.8) 
22 
(3.6) 
306 
(50.7) 
276 
(45.8) 
21 
(3.5) 
22F 
(598) 
88 
(14.7) 
425 
(71.1) 
85 
(14.2) 
17 
(2.8) 
25 
(4.2) 
26 
(4.3) 
7 
(1.2) 
92 
(15.4) 
144 
(24.1) 
270 
(45.2) 
17 
(2.8) 
305 
(51.0) 
268 
(44.8) 
25 
(4.2) 
3 
(494) 
94 
(19.0) 
337 
(68.2) 
63 
(12.8) 
13 
(2.6) 
6 
(1.2) 
23 
(4.7) 
9 
(1.8) 
75 
(15.2) 
143 
(28.9) 
202 
(40.9) 
23 
(4.7) 
253 
(51.2) 
221 
(44.7) 
20 
(4.0) 
12F 
(291) 
219 
(75.3) 
63 
(21.6) 
9 
(3.1) 
6 
(2.1) 
7 
(2.4) 
4 
(1.4) 
9 
(3.1) 
129 
(44.3) 
74 
(25.4) 
57 
(19.6) 
5 
(1.7) 
154 
(52.9) 
128 
(44.0) 
9 
(3.1) 
11A 
(269) 
46 
(17.1) 
205 
(76.2) 
18 
(6.7) 
5 
(1.9) 
14 
(5.2) 
4 
(1.5) 
7 
(2.6) 
43 
(16.0) 
77 
(28.6) 
117 
(43.5) 
2 
(0.7) 
136 
(50.6) 
127 
(47.2) 
6 
(2.2) 
9N 
(242) 
43 
(17.8) 
160 
(66.1) 
39 
(16.1) 
5 
(2.1) 
3 
(1.2) 
1 
(0.4) 
4 
(1.7) 
41 
(16.9) 
94 
(38.8) 
84 
(34.7) 
10 
(4.1) 
128 
(52.9) 
108 
(44.6) 
6 
(2.5) 
8 
(241) 
68 
(28.2) 
140 
(58.1) 
33 
(13.7) 
8 
(3.3) 
2 
(0.8) 
2 
(0.8) 
10 
(4.1) 
77 
(32.0) 
72 
(29.9) 
64 
(26.6) 
6 
(2.5) 
140 
(58.1) 
91 
(37.8) 
10 
(4.1) 
33F 
(225) 
47 
(20.9) 
157 
(69.8) 
21 
(9.3) 
7 
(3.1) 
20 
(8.9) 
8 
(3.6) 
8 
(3.6) 
39 
(17.3) 
55 
(24.4) 
81 
(36.0) 
7 
(3.1) 
98 
(43.6) 
119 
(52.9) 
8 
(3.6) 
15A 
(220) 
31 
(14.1) 
172 
(78.2) 
17 
(7.7) 
4 
(1.8) 
12 
(5.5) 
8 
(3.6) 
0 28 
(12.7) 
38 
(17.3) 
126 
(57.3) 
4 
(1.8) 
96 
(43.6) 
120 
(54.5) 
4 
(1.8) 
6C 
(205) 
43 
(21.0) 
131 
(63.9) 
31 
(15.1) 
3 
(1.5) 
5 
(2.4) 
6 
(2.9) 
3 
(1.5) 
26 
(12.7) 
43 
(21.0) 
116 
(56.6) 
3 
(1.5) 
119 
(58.0) 
81 
(39.5) 
5 
(2.4) 
Total 
(4092) 
868 
(21.2) 
2701 
(66.0) 
523 
(12.8) 
109 
(2.7) 
125 
(3.1) 
157 
(3.8) 
122 
(3.0) 
873 
(21.3) 
1089 
(26.6) 
1499 
(36.6) 
118 
(2.9) 
2103 
(51.4) 
1853 
(45.3) 
136 
(3.3) 
a NG, information not given.    673 
 674 
 675 
 Table 2: Pneumococcal pilus presence demonstrated by the eleven most predominant S. pneumoniae 676 
serotypes collected by the SAVE 2011-2015 study. 677 
Serotype (n*) Genotype % with Genotype (n) % with Genotype that are MDR (n) 
7F (701) PI-1 0 0 
 PI-2 97.4 (683) 0.3 (2) 
 Dual 0 0 
 None 2.6 (18) 5.6 (1) 
19A (578) PI-1 44.5 (257) 5.1 (13) 
 PI-2 0.9 (5) 40.0 (2) 
 Dual 21.1 (122) 95.9 (117) 
 None 33.6 (194) 9.3 (18) 
22F (584) PI-1 0 0 
 PI-2 0 0 
 Dual 0 0 
 None 100 (584) 1.0 (6) 
3 (480) PI-1 0.4 (2) 0 
 PI-2 0 0 
 Dual 0 0 
 None 99.6 (478) 2.5 (12) 
12F (276) PI-1 0 0 
 PI-2 0 0 
 Dual 0 0 
 None 100 (276) 1.4 (4) 
11A (241) PI-1 1.2 (3) 0 
 PI-2 67.2 (162) 0 
 Dual 0 0 
 None 31.5 (76) 2.6 (2) 
9N (198) PI-1 0.5 (1) 0 
 PI-2 0 0 
 Dual 0 0 
 None 99.5 (197) 0.5 (1) 
 8 (217) PI-1 0.5 (1) 0 
 PI-2 0 0 
 Dual 0 0 
 None 99.5 (216) 0.5 (1) 
33F (203) PI-1 0 0 
 PI-2 0 0 
 Dual 0.5 (1) 0 
 None 99.5 (202) 6.9 (14) 
15A (212) PI-1 28.8 (61) 0 
 PI-2 0 0 
 Dual 0 0 
 None 71.2 (151) 63.6 (96) 
6C (188) PI-1 8.5 (16) 6.3 (1) 
 PI-2 0 0 
 Dual 0 0 
 None 91.5 (172) 3.5 (6) 
All (3878) PI-1 8.8 (341) 4.1 (14) 
 PI-2 21.9 (850) 0.5 (4) 
 Dual 3.2 (123) 95.1 (117) 
 None 66.1 (2564) 6.3 (161) 
*, n with complete results for both PCR reactions. Isolates that maintained double positive or double 678 
negative results after repeating were excluded.679 
 Table 3: Resistance genes identified in 160a S. pneumoniae isolates from the SAVE study sequenced using whole genome sequencing. 680 
 681 
Antimicrobial 
Class 
Resistance 
Gene 
Count (%) S/I/R (n) %S %NS Serotypes %MDR 
β-Lactam pbp2B only 17 (10.6) 3/14/0 17.6 82.4 6ABC(4), 7F(1), 8(1), 10A (1), 15A(5), 19A(1), 22F(2), 
23B(2) 
58.8 (10) 
 
pbp2X only 10 (6.3) 10/0/0 100 0 3(4), 5(1), 11A(1), 12F(1), 15B(1), 16F(1), 19A(1) 50.0 (5) 
 
1A+2B 1 (0.6) 0/1/0 0 100 24F(1) 0 
 
1A+2X 1 (0.6) 0/1/0 0 100 35B(1) 0 
 
2B+2X 5 (3.1) 1/3/1 20.0 80.0 6C(2), 15A(2), 19A(1) 80.0 (4) 
 
1A+2B+2X 41 (25.6) 0/9/32 0 100 6B(1), 9V(3), 15AB(7), 19AF(23), 23F(1), 29(1), 35B(5) 85.4 (35) 
 None 85 (53.1) 82/3/0 96.5 3.5 - 11.8 (10) 
Macrolide/ mefA only 17 (10.6) 1/2/14b 5.9 94.1 6ABC(5), 9V(2), 14(2), 12F(1), 15B(1), 19A(1), 29(1), 
35B(4) 
29.4 (5) 
Lincosamide/ ermB only 48 (30.0) 1/1/46b 2.1 97.9 3(6), 6BC(3), 7F (1), 8(1), 9N(1), 11A(2), 12F(2), 
15AB(14), 17F(2), 19A(7), 22F(3), 23AF(2), 24F(1), 
33F(3) 
81.3 (39) 
Streptogramin 
  
9/0/39c 18.8 81.2  
 
Dual 18 (11.2) 1/2/15b 5.6 94.4 
19A(17), 19F(1) 100 (18)    
7/0/11c 38.9 61.1 
 None 77 (48.1) 76/0/1 98.7 1.3 
- 2.6 (2) 
   77/0/0 100 0 
 682 
  683 
 Tetracycline tetM 64 (40.0) 4*/0/60 6.3 93.7 3(6), 6BC(3), 7F(1), 8(1), 9N(1), 10A(1), 11A(1), 12F(2),  
15AB (14), 17F(2), 19AF(25), 22F(2), 23F(1), 24F(1), 
33F(3) 
89.1 (57) 
      
 
 None 96 (60.0) 93/2/1 96.9 3.1    - 7.3 (7) 
Fluoroquinolone parC S79 only 3 (1.9) 1/0/2d 33.3 66.7 19A(2), 22F(1) 66.7 (2) 
 
gyrA S81 only 3 (1.9) 2/1/0e 66.7 33.3 9N(1), 19A(1), 35B(1) 33.3 (1) 
 
both 8 (5.0) 0/0/8d 0 100 
6A(2), 11A(1), 19A(1), 22F(2), 23F(2) 50.0 (4)    
0/4/4e 0 100 
 None 146 (91.3) 146/0/0d 100 0 
   - 
38.4 (56) 
   146/0/0e 100 0  
Trimethoprim/ folA I100L only 0 - - - - - 
Sulfamethoxazole folP mutation 
only 
10 (6.3) 2/7/1 20.0 80.0 5(1), 15BC(4), 18C(1), 19A(1), 23B(1), 24F(1), 33F(1) 10.0 (1) 
 
both 37 (23.1) 0/1/36 0 100 5(1), 6ABC(4), 9V(3), 10A(1), 11A(2), 15AB(2), 
19AF(21), 23F(1), 35B(2) 
83.8 (31) 
 None 113 (70.6) 112/0/1 99.1 0.9 - 28.3 (32) 
Chloramphenicol cat 8 (5.0) 0/0/8 0 100 3(5), 15B(1), 19A(1), 23F(1) 100 (8) 
 None 152 (95.0) 152/0/0 100 0 - 36.8 (56) 
 684 
S, susceptible; I, intermediate; R, resistant; NS, non-susceptible. a, isolates without full susceptibility results were excluded from the analysis.  685 
b, susceptibility to clarithromycin. c, susceptibility to clindamycin. d, susceptibility to levofloxacin. e, susceptibility to moxifloxacin. *Discrepant 686 
isolates that possessed tetM but were susceptible to doxycycline. 687 
  688 
 Figure 1: Minimum spanning tree (generated by PHYLOViZ 2.0) of MLST sequence types demonstrated by the eleven most predominant S. 689 
pneumoniae serotypes collected by the SAVE 2011-2015 study. Green outlines indicate a group founder; light blue outlines indicate relatedness 690 
to founder; numbers indicate the number of differences between the MLST profiles of the two connected nodes (≤ 2 indicates the two nodes are 691 
part of a cluster). Clusters with relation to PMEN international clones are listed along with the representative serotype for that clone. 692 
 693 
 694 
 695 
  696 
  697 
 Figure 2: Maximum likelihood tree (generated using PhyML and visualized with FigTree) of 162 isolates from the SAVE 2011-2014 study and 30 698 
background isolates from the BESST 2007-2009 study. Clusters (as delineated by ClusterPicker) containing predominant serotypes collected by 699 
the SAVE study are coloured, and relation to PMEN international clones is listed along with the representative serotype for that clone. 700 
  701 
  702 
